Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Understanding the potential impact of a combination HIV prevention intervention in a hyper-endemic community.

Alsallaq RA, Baeten JM, Celum CL, Hughes JP, Abu-Raddad LJ, Barnabas RV, Hallett TB.

PLoS One. 2013;8(1):e54575. doi: 10.1371/journal.pone.0054575. Epub 2013 Jan 23.

2.

The potential impact and cost of focusing HIV prevention on young women and men: A modeling analysis in western Kenya.

Alsallaq RA, Buttolph J, Cleland CM, Hallett T, Inwani I, Agot K, Kurth AE.

PLoS One. 2017 Apr 12;12(4):e0175447. doi: 10.1371/journal.pone.0175447. eCollection 2017.

3.

Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia.

Vermund SH, Fidler SJ, Ayles H, Beyers N, Hayes RJ.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S221-7. doi: 10.1097/QAI.0b013e318299c3f4.

4.

Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.

Long EF, Stavert RR.

J Gen Intern Med. 2013 Oct;28(10):1294-301. doi: 10.1007/s11606-013-2417-1. Epub 2013 Apr 16.

5.

HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial.

Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, Bock P, Griffith S, Moore A, Watson-Jones D, Fraser C, Vermund SH, Fidler S; HPTN 071 (PopART) Study Team..

Trials. 2014 Feb 13;15:57. doi: 10.1186/1745-6215-15-57.

6.

Association of Medical Male Circumcision and Antiretroviral Therapy Scale-up With Community HIV Incidence in Rakai, Uganda.

Kong X, Kigozi G, Ssekasanvu J, Nalugoda F, Nakigozi G, Ndyanabo A, Lutalo T, Reynolds SJ, Ssekubugu R, Kagaayi J, Bugos E, Chang LW, Nanlesta P, Mary G, Berman A, Quinn TC, Serwadda D, Wawer MJ, Gray RH.

JAMA. 2016 Jul 12;316(2):182-90. doi: 10.1001/jama.2016.7292.

7.

The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.

Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB.

AIDS. 2013 Jan 28;27(3):447-58. doi: 10.1097/QAD.0b013e32835ca2dd.

PMID:
23296196
8.

HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa.

Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, Bershteyn A, Bloom DE, Cambiano V, Fraser C, Hontelez JA, Humair S, Klein DJ, Long EF, Phillips AN, Pretorius C, Stover J, Wenger EA, Williams BG, Hallett TB.

PLoS Med. 2012;9(7):e1001245. doi: 10.1371/journal.pmed.1001245. Epub 2012 Jul 10.

9.

Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial.

Iwuji CC, Orne-Gliemann J, Tanser F, Boyer S, Lessells RJ, Lert F, Imrie J, Bärnighausen T, Rekacewicz C, Bazin B, Newell ML, Dabis F; ANRS 12249 TasP Study Group..

Trials. 2013 Jul 23;14:230. doi: 10.1186/1745-6215-14-230.

10.

Estimating PMTCT's Impact on Heterosexual HIV Transmission: A Mathematical Modeling Analysis.

Khanna AS, Roberts ST, Cassels S, Ying R, John-Stewart G, Goodreau SM, Baeten JM, Murnane PM, Celum C, Barnabas RV.

PLoS One. 2015 Aug 11;10(8):e0134271. doi: 10.1371/journal.pone.0134271. eCollection 2015.

11.

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.

Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG.

Lancet. 2009 Jan 3;373(9657):48-57. doi: 10.1016/S0140-6736(08)61697-9. Epub 2008 Nov 27.

PMID:
19038438
12.

HIV prevention counseling intervention delivered during routine clinical care reduces HIV risk behavior in HIV-infected South Africans receiving antiretroviral therapy: the Izindlela Zokuphila/Options for Health randomized trial.

Fisher JD, Cornman DH, Shuper PA, Christie S, Pillay S, Macdonald S, Ngcobo N, Amico KR, Lalloo U, Friedland G, Fisher WA; SA Options Team..

J Acquir Immune Defic Syndr. 2014 Dec 15;67(5):499-507. doi: 10.1097/QAI.0000000000000348.

13.
14.

Dropout and re-enrollment: implications for epidemiological projections of treatment programs.

Klein DJ, Bershteyn A, Eckhoff PA.

AIDS. 2014 Jan;28 Suppl 1:S47-59. doi: 10.1097/QAD.0000000000000081.

PMID:
24468946
15.

Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidence.

Eaton JW, Hallett TB.

Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):16202-7. doi: 10.1073/pnas.1323007111. Epub 2014 Oct 13.

17.

High HIV testing uptake and linkage to care in a novel program of home-based HIV counseling and testing with facilitated referral in KwaZulu-Natal, South Africa.

van Rooyen H, Barnabas RV, Baeten JM, Phakathi Z, Joseph P, Krows M, Hong T, Murnane PM, Hughes J, Celum C.

J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):e1-8. doi: 10.1097/QAI.0b013e31829b567d.

18.

Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.

Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin Í, Delany S, Garnett GP, Gray G, Johnson L, McIntyre J, Rees H, Celum C.

PLoS Med. 2011 Nov;8(11):e1001123. doi: 10.1371/journal.pmed.1001123. Epub 2011 Nov 15.

19.

Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study.

Tanser F, Bärnighausen T, Hund L, Garnett GP, McGrath N, Newell ML.

Lancet. 2011 Jul 16;378(9787):247-55. doi: 10.1016/S0140-6736(11)60779-4.

20.

The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.

Long EF, Brandeau ML, Owens DK.

Ann Intern Med. 2010 Dec 21;153(12):778-89. doi: 10.7326/0003-4819-153-12-201012210-00004.

Supplemental Content

Support Center